GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (STU:QTS) » Definitions » Cyclically Adjusted Price-to-FCF

IQVIA Holdings (STU:QTS) Cyclically Adjusted Price-to-FCF : 33.54 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is IQVIA Holdings Cyclically Adjusted Price-to-FCF?

As of today (2024-05-28), IQVIA Holdings's current share price is €210.30. IQVIA Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €6.27. IQVIA Holdings's Cyclically Adjusted Price-to-FCF for today is 33.54.

The historical rank and industry rank for IQVIA Holdings's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:QTS' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 28.25   Med: 38.33   Max: 60.37
Current: 33.66

During the past years, IQVIA Holdings's highest Cyclically Adjusted Price-to-FCF was 60.37. The lowest was 28.25. And the median was 38.33.

STU:QTS's Cyclically Adjusted Price-to-FCF is ranked better than
52.38% of 63 companies
in the Medical Diagnostics & Research industry
Industry Median: 35.56 vs STU:QTS: 33.66

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

IQVIA Holdings's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €1.882. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €6.27 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


IQVIA Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for IQVIA Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Cyclically Adjusted Price-to-FCF Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 58.00 35.63 35.85

IQVIA Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.95 36.04 30.90 35.85 37.07

Competitive Comparison of IQVIA Holdings's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, IQVIA Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Cyclically Adjusted Price-to-FCF falls into.



IQVIA Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

IQVIA Holdings's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=210.30/6.27
=33.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, IQVIA Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.882/131.7762*131.7762
=1.882

Current CPI (Mar. 2024) = 131.7762.

IQVIA Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.273 100.560 0.358
201409 0.684 100.428 0.898
201412 1.462 99.070 1.945
201503 -0.586 99.621 -0.775
201506 0.248 100.684 0.325
201509 1.835 100.392 2.409
201512 1.382 99.792 1.825
201603 0.636 100.470 0.834
201606 0.073 101.688 0.095
201609 1.757 101.861 2.273
201612 1.454 101.863 1.881
201703 -0.088 102.862 -0.113
201706 0.581 103.349 0.741
201709 1.329 104.136 1.682
201712 0.517 104.011 0.655
201803 0.360 105.290 0.451
201806 0.820 106.317 1.016
201809 0.916 106.507 1.133
201812 1.202 105.998 1.494
201903 -0.123 107.251 -0.151
201906 1.041 108.070 1.269
201909 0.826 108.329 1.005
201912 2.039 108.420 2.478
202003 0.102 108.902 0.123
202006 1.535 108.767 1.860
202009 1.816 109.815 2.179
202012 2.416 109.897 2.897
202103 3.095 111.754 3.649
202106 1.678 114.631 1.929
202109 2.968 115.734 3.379
202112 2.306 117.630 2.583
202203 1.554 121.301 1.688
202206 0.832 125.017 0.877
202209 3.722 125.227 3.917
202212 1.948 125.222 2.050
202303 1.253 127.348 1.297
202306 1.196 128.729 1.224
202309 2.207 129.860 2.240
202312 2.823 129.419 2.874
202403 1.882 131.776 1.882

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IQVIA Holdings  (STU:QTS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


IQVIA Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings (STU:QTS) Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.